{"title":"Highlighted Lectures and Awards","authors":"","doi":"10.1111/ajco.70020","DOIUrl":"https://doi.org/10.1111/ajco.70020","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 S4","pages":"6-9"},"PeriodicalIF":1.6,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145443205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Program in Detail","authors":"","doi":"10.1111/ajco.70025","DOIUrl":"https://doi.org/10.1111/ajco.70025","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 S4","pages":"28-56"},"PeriodicalIF":1.6,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145443141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: Nanoliposomal irinotecan plus fluorouracil and folinic acid (NFF) has been used as a standard treatment for unresectable pancreatic cancer refractory to gemcitabine-based therapies. However, reports on the efficacy of NFF in older patients with pancreatic cancer, especially in those aged > 75 years, are limited. We retrospectively compared the efficacy and safety of NFF in older and younger patients.
Methods: We reviewed the clinical records of 161 consecutive patients with unresectable pancreatic cancer who were treated with NFF between June 2020 and May 2021. Patients ≥ 75 years old were classified as the older group. We compared the antitumor efficacy, safety, and survival of the older and younger groups. Geriatric nutritional risk index (GNRI) was used as a prognostic indicator in the older group.
Results: Overall, 26 and 135 patients were enrolled in the older and younger groups, respectively. The pretreatment characteristics of the two groups were not significantly different. Median overall survival and progression-free survival were 10.9 and 5.0 months, respectively, in the older group, versus 7.6 (p = 0.15) and 3.1 months (p = 0.29), respectively, in the younger group. There were no clinical differences in the adverse events or the overall response rates between the two groups. The older group with GNRI < 86 tended to have a shorter overall survival.
Conclusion: Older patients with pancreatic cancer may benefit from NFF to the same extent as younger patients without severe adverse events. GNRI needs further study as a predictor of NFF efficacy in older patients.
{"title":"Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 Study.","authors":"Atsuko Kakihara, Shigeyuki Takeshita, Mototsugu Shimokawa, Taiga Otsuka, Shiho Arima, Akio Ido, Taro Shibuki, Junichi Nakazawa, Keisuke Miwa, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Azusa Komori, Kazuo Nishikawa, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Kengo Tsuneyoshi, Hiroki Taguchi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi","doi":"10.1111/ajco.70041","DOIUrl":"https://doi.org/10.1111/ajco.70041","url":null,"abstract":"<p><strong>Aim: </strong>Nanoliposomal irinotecan plus fluorouracil and folinic acid (NFF) has been used as a standard treatment for unresectable pancreatic cancer refractory to gemcitabine-based therapies. However, reports on the efficacy of NFF in older patients with pancreatic cancer, especially in those aged > 75 years, are limited. We retrospectively compared the efficacy and safety of NFF in older and younger patients.</p><p><strong>Methods: </strong>We reviewed the clinical records of 161 consecutive patients with unresectable pancreatic cancer who were treated with NFF between June 2020 and May 2021. Patients ≥ 75 years old were classified as the older group. We compared the antitumor efficacy, safety, and survival of the older and younger groups. Geriatric nutritional risk index (GNRI) was used as a prognostic indicator in the older group.</p><p><strong>Results: </strong>Overall, 26 and 135 patients were enrolled in the older and younger groups, respectively. The pretreatment characteristics of the two groups were not significantly different. Median overall survival and progression-free survival were 10.9 and 5.0 months, respectively, in the older group, versus 7.6 (p = 0.15) and 3.1 months (p = 0.29), respectively, in the younger group. There were no clinical differences in the adverse events or the overall response rates between the two groups. The older group with GNRI < 86 tended to have a shorter overall survival.</p><p><strong>Conclusion: </strong>Older patients with pancreatic cancer may benefit from NFF to the same extent as younger patients without severe adverse events. GNRI needs further study as a predictor of NFF efficacy in older patients.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号